ISCT Joins Forces with Roche and Genzyme to Launch Cell Therapy Industry Partnership

Several companies in the cell therapy regenerative medicine market, including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza, and Life Technologies, will join the International Society for Cellular Therapy (ISCT, Vancouver, Canada) to launch a series of initiatives that will create greater strategic alignment within the industry and drive late-stage clinical development.
The ISCT Industry Task Force (ITF), comprising these major corporations along with internationally renowned clinicians and academics in cell therapy translation, rolled out a series of recommendations to re-charter the ISCT Commercialization Committee to drive the creation of forums for discussion of shared concerns on process and product development, business models, and clinical development, and to catalyze the development of consensus standards.
These companies remain engaged with ISCT as members on the commercialization committee to drive this agenda forward and are participating in the roll out of the first initiative to add value in the relationship between ISCT and Industry—the new ISCT Industry Community.
The community offers access to key opinion leaders in cell therapy translation including regulatory, scientific, process development, and clinical experts through focus group participation, and will drive priorities on the development of resources and initiatives to remove key obstacles to commercialization.